Skip to Main Content

Paper Details

<i>In Vivo</i> Epigenetic CRISPR Screen Identifies <i>Asf1a</i> as an Immunotherapeutic Target in <i>Kras</i>-Mutant Lung Adenocarcinoma.
Cancer Discov
114
2020
ASF1A, Asf1a, Asf1a deficiency, G12D, GM-CSF, KRAS, Kras, Kras G12D/, Kras-Mutant Lung Adenocarcinoma, LUAD, M1, M1-like macrophage, PD-1, T-, Trp53, anti-, anti-PD-1, histone chaperone, lung cancer, patients, single guide RNA, tumor, tumor cell, tumor cells, tumors
Author NameAffiliation
Peter S HammermanDana-Farber Cancer Institute
Peter S HammermanDana-Farber Cancer Institute
Jun QiDana-Farber Cancer Institute
Jun QiHarvard Medical School
  • 1 - 4

Datasets

Release 1.2